Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important

K P Hopfner1, H Brandstetter, A Karcher

  • 1Abteilung Strukturforschung, Max-Planck-Institut für Biochemie, D-82152 Martinsried, Germany.

The EMBO Journal
|January 10, 1998
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in survival of >3800 patients with metastatic colorectal cancer in Germany: results from a 16-year prospective longitudinal real-world data analysis.

ESMO real world data and digital oncology·2026
Same author

Cross-reactivity of triptans and sulfonamide antibiotics - a clinically relevant question?

Die Pharmazie·2024
Same author

Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC.

The European physical journal. C, Particles and fields·2022
Same author

Prospects for beyond the Standard Model physics searches at the Deep Underground Neutrino Experiment: DUNE Collaboration.

The European physical journal. C, Particles and fields·2021
Same author

Molecular basis of human ATM kinase inhibition.

Nature structural & molecular biology·2021
Same author

Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS).

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2019

Coagulation factor IXa (fIXa) exhibits low amidolytic activity compared to factor Xa (fXa). Engineering fIXa with fXa residues significantly enhanced its reactivity and substrate selectivity, offering therapeutic potential.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Enzymology

Background:

  • Coagulation factors IXa (fIXa) and Xa (fXa) share structural and functional similarities.
  • fIXa displays significantly lower amidolytic activity (10^4-fold) than fXa.
  • Understanding the determinants of fIXa's low reactivity is crucial for potential therapeutic applications.

Purpose of the Study:

  • To identify the structural determinants responsible for the low amidolytic activity of coagulation factor IXa (fIXa).
  • To engineer fIXa variants with enhanced reactivity and fXa-like properties.

Main Methods:

  • Expression of truncated variants of fIXa (rf9a) and fXa (rf10a) in Escherichia coli.
  • Determination of crystal structures of fIXa and fXa.
  • Site-directed mutagenesis to exchange active site components between rf9a and rf10a.

Related Experiment Videos

  • Assay of amidolytic activity and substrate selectivity of engineered variants.

    • Main Results:

    • Exchanging the 99 loop of fIXa dramatically increased its reactivity.
    • Combining four specific mutations, mimicking fXa residues, resulted in a 130-fold increase in fIXa amidolytic activity.
    • Engineered fIXa variants exhibited fXa substrate selectivity.
    • Narrowed S3/S4 subsite and distorted S1 subsite were identified as key defects in fIXa's poor reactivity.

    Conclusions:

    • The poor reactivity of fIXa stems from a narrowed S3/S4 subsite and a distorted S1 subsite.
    • Introducing fXa residues into fIXa can repair these defects, significantly enhancing activity and altering substrate specificity.
    • Engineered coagulation enzymes hold promise for diagnostic and therapeutic development.